Elevated concurrent carotid atherosclerosis rates in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) compared to non-alcoholic fatty liver disease (NAFLD): A cross-sectional observational study
- PMID: 39561692
- DOI: 10.1016/j.numecd.2024.10.006
Elevated concurrent carotid atherosclerosis rates in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) compared to non-alcoholic fatty liver disease (NAFLD): A cross-sectional observational study
Abstract
Background and aim: Non-alcoholic fatty liver disease (NAFLD) has been recognized as an independent risk factor for atherosclerotic cardiovascular disease. Recently, there has been a shift towards diagnosing metabolic dysfunction-associated fatty liver disease (MAFLD), offering simplified criteria and improved risk assessment. However, the association between MAFLD and carotid atherosclerosis remains poorly understood.
Methods and results: The study analyzed the association of concurrent carotid atherosclerosis between NAFLD and MAFLD patients with a retrospective cohort design. The study enrolled participants who underwent abdominal and carotid artery ultrasounds from a medical center in Taiwan. NAFLD and MAFLD were diagnosed based on imaging and specific criteria. Associations between NAFLD, MAFLD, and carotid atherosclerosis were analyzed using logistic regression. Among 11,194 participants, 57.1 % were diagnosed with fatty liver disease, among which the NAFLD-MAFLD group comprised 4689 individuals, with 900 in the NAFLD-only group and 669 in the MAFLD-only group. Significant demographic and clinical differences were observed between groups. Logistic regression showed that the MAFLD-NAFLD group and MAFLD-only group had significantly higher odds of concomitant carotid atherosclerosis. Among MAFLD patients, 65.5 % had concurrent carotid arteriosclerosis with an odds ratio of 2.35 compared to non-MAFLD patients. The odds ratios for variables in MAFLD patients, such as diabetes mellitus, Fibrosis-4(FIB-4), number of FIB-4 > 1.3, and number of NAFLD fibrosis score > -1.455 were all greater than 2.
Conclusions: MAFLD is associated with a higher prevalence of carotid atherosclerosis, compared to NAFLD. This suggests that MAFLD may serve as a significant risk factor for cardiovascular complications.
Keywords: Cardiovascular disease; Carotid atherosclerosis; Fatty liver disease.
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no competing interests related to the present study.
Similar articles
-
Letter to the Editor: Elevated concurrent carotid atherosclerosis rates in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) compared to non-alcoholic fatty liver disease (NAFLD): A cross-sectional observational study.Nutr Metab Cardiovasc Dis. 2025 Jun;35(6):103980. doi: 10.1016/j.numecd.2025.103980. Epub 2025 Mar 8. Nutr Metab Cardiovasc Dis. 2025. PMID: 40189993
-
Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.Hepatol Int. 2023 Apr;17(2):350-356. doi: 10.1007/s12072-022-10449-x. Epub 2022 Dec 5. Hepatol Int. 2023. PMID: 36471232
-
Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.Liver Int. 2023 Aug;43(8):1691-1698. doi: 10.1111/liv.15591. Epub 2023 Jun 20. Liver Int. 2023. PMID: 37337780
-
Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease.Am J Med Sci. 2024 Dec;368(6):557-568. doi: 10.1016/j.amjms.2024.06.022. Epub 2024 Jun 27. Am J Med Sci. 2024. PMID: 38944203 Review.
-
An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.Clin Gastroenterol Hepatol. 2023 Mar;21(3):619-629.e7. doi: 10.1016/j.cgh.2021.11.038. Epub 2021 Dec 4. Clin Gastroenterol Hepatol. 2023. PMID: 34871813 Review.
Cited by
-
Diagnosis and Monitoring of Metabolic Dysfunction Associated with Fatty Liver Disease in Primary Care Patients with Risk Factors-EsteatoGal Study.J Clin Med. 2025 Apr 29;14(9):3089. doi: 10.3390/jcm14093089. J Clin Med. 2025. PMID: 40364120 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical